ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 27, 2009
WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 28, 2009--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceuticals company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, invites investors, journalists and the general public to listen to a live webcast of the Company's investment community meeting on February 27, 2009. The meeting will include a discussion of ImmunoGen's technology and product pipeline, partnerships and financials, and the Company's strategy for growth. The webcast will begin at 8:30 am ET and may be accessed through the Investor Information section of the Company's website, www.immunogen.com. The meeting is expected to last approximately three hours, including a short break. An archive of the webcast will be available on the Company's website through March 13, 2009.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's TAP technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis, Biogen Idec, and Biotest also are testing TAP compounds in the clinic, and the naked antibody AVE1642 is in clinical trials through the Company's collaboration with sanofi-aventis. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.
CONTACT:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
